论文部分内容阅读
药物支架的出现是介入性心脏病学一个里程碑,但是由于其有增加晚期血栓形成的潜在风险,使其应用于病变血栓负荷重的急性心肌梗死受到质疑。近年来关于药物支架应用于急性心肌梗死的随机对照试验及临床注册试验显示其应用于急性心肌梗死患者与裸支架相比并不增加病死率、心肌梗死率及支架内血栓发生率,且明显降低靶病变及靶血管的血运重建,但已有研究的随访时间尚不够长,仍需要样本量更大、随访时间更长的研究以进一步证实药物支架的长期安全性与有效性。
The emergence of drug stents is a milestone in interventional cardiology, but its potential to increase the risk of advanced thrombosis has challenged its use in the treatment of acute myocardial infarction with a thrombotic load. In recent years, the randomized controlled trials and clinical trials of drug scaffolds for acute myocardial infarction have shown that their application to acute myocardial infarction patients did not increase mortality, myocardial infarction rate and stent thrombosis compared with bare-metal stents and was significantly lower Target lesion and target vessel revascularization. However, the follow-up study has not been long enough, and a larger sample and longer follow-up study is needed to further confirm the long-term safety and effectiveness of the drug scaffold.